Clinical trials: Prostatic Disease
Prostate Cancer
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor.
- Trial name
- NCT00400517
- Testing
- sargramostim, thalidomide, conventional surgery
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Prostate Cancer
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced…
- Trial name
- Triptocare (NCT01020448)
- Testing
- Triptorelin (Decapeptyl®)
- Where
- 59 sites in Belgium, Denmark and 8 more
- Volunteers
- 339 people
- Sponsor
- Ipsen
Benign Prostatic Hyperplasia
Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression
The purpose of this study is: To assess safety of Afalaza drug within 12 months in patients with symptoms of benign prostatic hyperplasia (BPH) and risk of progression.
- Trial name
- NCT01716104
- Testing
- Afalaza
- Where
- 16 sites in Russia, Ukraine
- Volunteers
- 260 people
- Sponsor
- Materia Medica Holding
Prostate Cancer
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion(standard of care and not a part of study)
- Trial name
- NCT00828308
- Testing
- Ixabepilone, Prostatectomy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brown University
Prostatic Neoplasms
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
- Trial name
- SPARTAN (NCT01946204)
- Testing
- Apalutamide
- Where
- 379 sites in United States, Australia and 23 more
- Volunteers
- 1,207 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Prostatic Neoplasms
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
This is a multicentered, open label, randomized phase II trial of PROSTVAC or ipilimumab or the combination of PROSTVAC and ipilimumab as neoadjuvant therapy in patients with localized prostate cancer.
- Trial name
- NCT02506114
- Testing
- PROSTVAC V/F, Ipilimumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Lawrence Fong
Metastatic Castration Resistant Prostate Cancer
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
The purpose of the study was to understand if there was benefit in continued treatment with a medicine called enzalutamide, when starting treatment with docetaxel and prednisolone (a standard chemotherapy for prostate cancer)…
- Trial name
- PRESIDE (NCT02288247)
- Testing
- Enzalutamide, Docetaxel, Prednisolone
- Where
- 89 sites in Austria, Belgium and 14 more
- Volunteers
- 688 people
- Sponsor
- Astellas Pharma Europe Ltd.
Prostate Cancer
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
- Trial name
- NCT06462014
- Testing
- Relugolix
- Where
- United States
- Volunteers
- 507 people
- Sponsor
- Pfizer
Prostate Cancer
Platelet Rich Plasma During Radical Prostatectomy
Can platelet rich plasma applied to nerve bundles at time of surgery help the nerve bundles heal? Subjects undergoing a Radical Prostatectomy who meet study inclusion/exclusion criteria will be consented to receive an…
- Trial name
- NCT02957149
- Testing
- Autologous Platelet-Rich Plasma, Angel Concentrated Platelet Rich Plasma System
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Prostate Cancer
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if…
- Trial name
- STEEL (NCT03809000)
- Testing
- Radiation Therapy, Enzalutamide, Bicalutamide
- Where
- 108 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- RTOG Foundation, Inc.
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- Neptune II (NCT01021332)
- Testing
- tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
- Where
- 70 sites in Austria, Belarus and 9 more
- Volunteers
- 1,067 people
- Sponsor
- Astellas Pharma Europe B.V.
Prostate Cancer
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Primary Objective: To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m^2 (Arm A) or 20 mg/m^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS) in participants with metastatic…
- Trial name
- FIRSTANA (NCT01308567)
- Testing
- Cabazitaxel (XRP6258), Docetaxel (XRP6976), Prednisone
- Where
- 167 sites in United States, Australia and 23 more
- Volunteers
- 1,168 people
- Sponsor
- Sanofi
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
This phase Ib trial studies how well pembrolizumab works with combination chemotherapy in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate that has spread to nearby tissue or lymph nodes…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03582475
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body.
- Trial name
- NCT01309672
- Testing
- abiraterone acetate, Prednisone
- Where
- 205 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy may be effective treatment for prostate cancer.
- Trial name
- NCT00002651
- Testing
- bicalutamide, goserelin acetate, clinical observation
- Where
- 14 sites in Canada
- Volunteers
- 3,040 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
The WINGMEN trial aims to understand how a hormone-like protein called insulin-like growth factor (IGF) helps prostate cancers grow and become aggressive.
- Trial name
- WINGMEN (NCT05110495)
- Testing
- Xentuzumab
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Oxford
Hormone-Sensitive Prostate Cancer
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in…
- Trial name
- CAPItello-281 (NCT04493853)
- Testing
- Capivasertib, Abiraterone Acetate
- Where
- 323 sites in United States, Argentina and 30 more
- Volunteers
- 1,012 people
- Sponsor
- AstraZeneca
Prostate Cancer, Prostatic Neoplasms
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer
- Trial name
- NCT01020305
- Testing
- Temsirolimus, Casodex (bicalutamide)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sandy Srinivas
Prostate Cancer
Use of Hypothermia During Robotic Prostatectomy
Robotic assisted laparoscopic radical prostatectomy (RLP) has gained widespread acceptance as a standard treatment for clinically localized prostate cancer.
- Trial name
- NCT00915031
- Testing
- UroCool
- Where
- United States
- Volunteers
- 738 people
- Sponsor
- University of California, Irvine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.